Compare Novavax Inc (NVAX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Revvity Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Revvity Inc trades at $110.7 (market cap $11.87B). The key difference: Revvity Inc is far larger — about 9.1× Novavax Inc's market cap, and Revvity Inc pays a 0.26% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RVTY | |
|---|---|---|
Market Cap | $1.30B | $11.87B |
Sector | Health | Technology |
52-Week High | $11.19 | $117.75 |
52-Week Low | $6.22 | $82.26 |
Enterprise Value | $800.50M | $14.36B |
Dividend Yield | — | 0.26% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
